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Adrenal functionmight be impaired in patientswith primary hypothyroidism.Theobjectivewas to evaluate adrenocortical function
using the low-dose cosyntropin test in patients with primary hypothyroidism. Consequently a prospective, longitudinal, controlled
study of sixty adult patients with primary hypothyroidism was carried out. Patients naı¨ve to L-T4 treatment were compared with
control participants. A low-dose cosyntropin test was done before and after L-T4 therapy. Thirty and sixty minutes after the low-
dose cosyntropin, the mean cortisol values were lower in the cases group (612.6 ± 133.1 and 603.4 ± 153.7 nmol/L) when compared
to the control group (677.0 ± 82.4 and 669.9 ± 83.7 nmol/L) (𝑃 = 0.001 and 0.003), respectively. After L-T4 therapy, this difference
was lost. Four out of 60 cases (6.7%) taking a cortisol cutoff value of 500mmol/L and 11 out of 60 (18.3%) having 550mmol/L as the
cutoff had adrenal insufficiency before L-T4 therapy. After L-T4 therapy, 50% and 81% of the cases had normal cortisol response. In
conclusion, patients with different degrees of intensity of primary hypothyroidism had improved cortisol response after reaching
euthyroidism.The incidence of adrenal insufficiency was 6.7–18.3% and more than 50% of the cases had a normal cortisol response
after L-T4 therapy.
1. Introduction
Thyroid gland dysfunction is a highly prevalent disorder in
day-to-day clinical practice. In fact, one of the most common
reasons for primary care consult is primary hypothyroidism.
Recent studies have found up to 25% prevalence in women
aged 60 and over [1–5]. The majority of these cases are either
subclinical or minimally symptomatic primary hypothy-
roidism [6]. The current widespread availability of thyroid
function tests has allowed frequent and early detection of
this disorder despite a low-index of clinical suspicion. In
consequence, severe primary hypothyroidism is now seldom
diagnosed. It is common practice to initiate levothyroxine
(L-T4) replacement together with glucocorticoids in extreme
conditions, such as myxedema coma [7]. Once patients are
clinically stable, glucocorticoids are discontinued. This ther-
apeutic approach is based on small series of cases that have
described transient adrenocortical impairment due to thyroid
dysfunction and vice versa [8–15]. Most of the evidence,
however, has methodological design problems that make the
clinical implications of these conclusions uncertain.
Some nondistinctive clinical manifestations of hypothy-
roidism and adrenocortical insufficiencymay overlap, partic-
ularlly in the musculoskeletal and neurological systems [16].
After starting L-T4 therapy in patients with hypothyroidism,
some of these symptoms may worsen due to myxedema
resolution or temporary adrenocortical dysfunction [17]. An
equilibrium between low cortisol secretion and its decreased
metabolism could lead to apparently normal basal serum and
urine cortisol values [8, 11]. A transitory low glucocorticoid
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production has been identified in cases with severe hypothy-
roidism but assessment of glucocorticoid functional reserve
in compensated and mild to moderate cases of primary
hypothyroidism has not been well elucidated. Furthermore,
the higher sensitivity of the low-dose cosyntropin test has not
been explored before L-T4 therapy and at follow-up in these
patients [18].
Accordingly, a prospective, longitudinal, and controlled
study was carried out to evaluate adrenocortical gluco-
corticoid function using the low-dose cosyntropin test, in
patients with subclinical, mild-moderate, and severe pri-
mary hypothyroidism.The primary endpoint was to contrast
the cortisol response to low-dose cosyntropin before L-T4
replacement and after normalization of thyroid function tests,
between groups and in each category and, furthermore, to
compare the cortisol values before and after L-T4 replacement
in cases versus their controls. A secondary endpoint was to
identify the prevalence of transient or permanent adrenocor-
tical insufficiency.
2. Subjects and Methods
2.1. Subjects. After obtaining approval from the Research and
Ethics Committee and signed informed consent from each
subject, we began the study. Patients were recruited through
the internal medicine, primary care, and endocrinology
clinics of the “Dr. Jose´ E. Gonza´lez” University Hospital. A
total of 60menorwomen, aged 18 to 70 years, with a diagnosis
of primary hypothyroidism andnaı¨ve to L-T4 treatment, were
included. Primary hypothyroidism was documented by the
results of the total and free thyroxin levels (TT4 and FT4,
resp.), thyrotropin (TSH) values, and positive antibodies to
thyroid peroxidase. Cases were classified into three groups:
subclinical primary hypothyroidism ((group #1) (𝑛 = 30)
(normal TT4 and FT4 values with an elevated TSH result but
below 10 𝜇U/mL)), mild/moderated hypothyroidism ((group
#2) (𝑛 = 15) (low TT4 and FT4 associated with a TSH
value between 20 and 40 𝜇U/mL + mild symptoms)), and
severe hypothyroidism ((group #3) (𝑛 = 15) (very low
TT4 and FT4 associated with a TSH value > 100 𝜇U/mL +
intense symptoms)). A complete clinical history and physical
examination were performed in all participants.We excluded
individuals with other endocrinopathies, glucocorticoid use
in the last 24 months, and current use of oral/nonoral
contraceptives or drugs that may interfere with cortisol
metabolism, transport, or the hypothalamo-pituitary-adrenal
axis. An age and gender matched control group (𝑛 = 60) of
healthy subjects was recruited from the primary care clinic.
2.2. Study Protocol. To perform a low-dose cosyntropin test,
a solution was prepared from serial dilutions in normal
saline of one vial of 250𝜇g synthetic ACTH (Cortrosyn,
Organon Inc., West Orange, NJ, USA), first to 50 𝜇g/mL,
then to 5 𝜇g/mL, and finally to the 1 𝜇g/mL concentration.
The vials were maintained refrigerated at 4∘C for a 3-month
period. All participants, cases and controls, underwent a
1 𝜇g cosyntropin dose test. After overnight fasting, between
8 and 9 h, an intravenous plastic catheter was inserted into
a forearm vein and a baseline blood sample was drawn for
measurement of basal cortisol one minute before each test.
Subsequently, 1 𝜇g ACTHwas injected as a bolus through the
catheter and flushed afterwards with 10mL of normal saline.
Blood samples for serumcortisolwere taken at 30 and 60min.
All samples were centrifuged, separated immediately, and
frozen at −20∘C. A serum cortisol value equal to or greater
than 500 nmol/L at 30 or 60min after stimulationwas defined
as a normal glucocorticoid response [18–20]. Five hundred
and fifty nmol/L was an alternate cutoff value that was also
examined [20, 21].
A low-dose cosyntropin test was carried out at baseline in
all cases (before starting L-T4 therapy) and repeated 16 weeks
later during follow-up, once thyroid function tests (TT4, FT4,
and TSH) were documented to be within normal values. All
cases received L-T4 replacement therapy as recommended
[12]. In the control group a low-dose cosyntropin test was
performed only at baseline.
2.3. Measurements. Thyroid function testing included mea-
surement of TT4, FT4, and TSH. Total and free thyroxin were
measured using a commercial kit for electrochemilumines-
cence (Modular Analytics E170, Roche/Hitachi Diagnostics,
Mannheim,Germany). Intra-assay variation coefficientswere
3.7, 3.4, and 4.2% and 2.7, 2.6, and 3.6% for low, medium, and
high TT4 and FT4 values, respectively. TSH was measured
using a commercial electrochemiluminescence kit (Modu-
lar Analytics E170, Roche/Hitachi Diagnostics, Mannheim,
Germany). Intra-assay variation coefficients were 7.2, 3.2, and
3.3% for low, medium, and high TSH values, respectively.
Serum cortisol was measured using a commercial RIA kit
(Elecsys 2010, Roche/Hitachi Diagnostics, Mannheim, Ger-
many). Intra-assay variation coefficients were 1.6, 1.5, and
1.6% for low, medium, and high cortisol values, respectively.
All samples were assessed twice.
2.4. Statistical Analysis. All results are reported as mean ±
standard deviation unless otherwise stated. A 𝑃 value equal
to or less than 0.05 was considered statistically significant.
Descriptive statistical analysis was used for quantitative
variables, measures of central tendency, and dispersion. In
the case of qualitative variables, frequencies were obtained.
To compare differences between basal and follow-up cortisol
responses within each patient group and between patients
and controls, paired and unpaired Student’s 𝑡 tests were used,
respectively. The statistical analysis was performed with IBM
SPSS Statistics 20.0 (SPSS Inc., Armonk, NY).
3. Results
3.1. Study Population. Thedemographic characteristics of the
study participants are shown in Table 1.There were 30, 15, and
15 participants in groups 1, 2, and 3, respectively.Themajority
of cases were between 18 and 60 years of age and, as expected,
mostwerewomen (75%).Therewas no statistically significant
difference in age between cases and age-gender matched
controls (𝑃 = 0.83). All cases and controls completed the
study.
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Table 1: Demographic characteristics of the participants.
Cases Cases Controls
Group 1 (𝑛 = 30) Group 2 (𝑛 = 15) Group 3 (𝑛 = 15) Total (𝑛 = 60) Total (𝑛 = 60)
Age—yr. 42.0 ± 12.6 43.8 ± 12.8 41.2 ± 12.7 42.3 ± 12.8 41.8 ± 12.0
Female no. (%) 24 (40.0) 11 (18.3) 10 (16.6) 45 (75.0) 45 (75.0)
Male no. (%) 6 (10.0) 4 (6.6) 5 (8.3) 15 (25.0) 15 (25.0)
18–40 yrs no. (%) 13 (21.7) 7 (11.6) 6 (10.0) 26 (43.3) 26 (43.3)
41–60 yrs no. (%) 14 (23.4) 5 (8.3) 8 (13.3) 27 (45.0) 27 (45)
>60 yrs no. (%) 3 (5.0) 3 (5.0) 1 (1.6) 7 (11.6) 7 (11.6)
Group 1 denotes subclinical hypothyroidsm; Group 2: mild/moderate hypothyroidsm; Group 3: severe hypothyroidsm; Yrs: years; %: percentage. Plus-minus
values are means ± standard deviation.
Table 2: Comparative cortisol values to cosyntropin before L-T4
replacement therapy between cases and their age-matched controls
(nmol/L).
Cases (𝑛 = 60) Controls (𝑛 = 60) 𝑃 value
All (𝑛 = 60)
0min 357.3 ± 144.8 369.2 ± 91.4 0.58
30min 612.6 ± 133.1 677.0 ± 82.4 0.001∗
60min 603.4 ± 153.7 669.9 ± 83.7 0.003∗
Group 1 (𝑛 = 30)
0min 384.6 ± 152.2 383.3 ± 110.5 0.96
30min 652.5 ± 101.3 673.2.0 ± 79.1 0.38
60min 618.3 ± 177.0 679.1 ± 95.6 0.10
Group 2 (𝑛 = 15)
0min 346.9 ± 148.5 348.6 ± 85.9 0.97
30min 636.5 ± 112.8 663.7 ± 108.1 0.36
60min 598.9 ± 135.0 686.5 ± 66.3 0.03∗
Group 3 (𝑛 = 15)
0min 348.9 ± 157.5 361.7 ± 40.4 0.76
30min 540.9 ± 178.7 687.9 ± 61.6 0.005∗
60min 611.7 ± 115.6 634.8 ± 66.32 0.50
All values given in nmol/L to convert to mg/dL are divided by 27.59.
∗Significant at 𝑃 of ≤0.05.
3.2. Assessment before Levothyroxine Therapy
3.2.1. Cases versus Controls: Comparison of Cortisol Values of
All Cases and Controls. Mean baseline (0min) cortisol value
between all cases (357.3±144.8 nmol/L) and controls (369.2±
91.4 nmol/L) was not statistically significant (𝑃 = 0.58). See
Table 2.Thirty and sixtyminutes after the cosyntropin test the
mean cortisol value was statistically lower in the cases group
(612.6 ± 133.1 and 603.4 ± 153.7 nmol/L) when compared to
the control group (677.0±82.4 and 669.9±83.7 nmol/L) (𝑃 =
0.001 and 0.003), respectively.
3.2.2. Cases versus Controls: Comparison of Cortisol Values
by Groups (Subclinical, Mild/Moderate, and Severe). Com-
parison of the cortisol values (baseline, 30 and 60 minutes)
between group 1 and their controls was not statistically
different. When group 2 was compared with controls a lower
mean cortisol value at 60-minute time (598.9 ± 135.0 nmol/L,
686.5 ± 66.3 nmol/L, resp.) was observed in the case group
(𝑃 = 0.03). Group 3 had a lower cortisol value at 30 min-
utes (540.9 ± 178.7 nmol/L) when compared with controls
(687.9 ± 61.6 nmol/L). All other cortisol values, even though
lower in cases than in controls, were not statistically different.
See Table 2.
3.2.3. Comparison of Cortisol Values between Cases Groups
(Subclinical, Mild/Moderate, and Severe). Mean baseline cor-
tisol values were not different between all three groups of
cases (384.6 ± 152.2 SD, 346.9 ± 148.5 SD, and 349.0 ±
157.5 nmol/L). Groups 1 versus 2, 2 versus 3, and 1 versus
3 resulted in a 𝑃 value of 0.43, 0.48, and 0.46, respectively.
At 30-minute time there was a statistical difference between
groups 1 versus 3 and 2 versus 3 (𝑃 = 0.01 and 0.04, resp.)
due to a lower mean cortisol value in group 3 participants.
This significant difference disappeared at 60-minute time
comparison between groups 1 versus 2, 1 versus 3, and 2 versus
3 (𝑃 = 0.12, 0.83, and 0.11, resp.). See Table 3.
3.3. Assessment after Levothyroxine Therapy
3.3.1. Cases versus Controls: Comparison of Cortisol Values
of All Cases and Controls. Once levothyroxine replacement
reached normalization of the thyrotropin values in all cases,
comparison of the mean serum cortisol values at baseline, 30,
and 60 minutes after stimulation against the control group
did not show any difference. See Table 3.
3.3.2. Cases versus Controls: Comparison of Cortisol Values
by Groups (Subclinical, Mild/Moderate, and Severe). Mean
serum cortisol values at baseline, 30, and 60 minutes after
cosyntropin stimulation did not reach statistical differences
in groups 1, 2, and 3 when compared with their controls. See
Table 4.
3.3.3. Comparison of Cortisol Values between Cases Groups
(Subclinical, Mild/Moderate, and Severe). Mean cortisol val-
ues were different between group 2 and group 3 at baselines
302.3 ± 87.4 and 442.5 ± 198.4 nmol/L; 𝑃 = 0.009. The rest of
the comparisons between groups at baseline and at 30 and 60
minutes were no different. See Table 3.
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Table 3: Glucocorticoid functional assessment in the cases by groups (nmol/L).
Group 1 1 versus 2 Group 2 2 versus 3 Group 3 1 versus 3
𝑃 𝑃 𝑃
0min† 384.6 ± 152.2 0.43 346.9 ± 148.5 0.48 349.0 ± 157.5 0.46
0min‡ 391.9 ± 176.3 0.07 302.3 ± 87.4 0.009∗ 442.5 ± 198.4 0.38
30min† 652.5 ± 101.3 0.66 636.5 ± 112.8 0.04∗ 540.9 ± 178.7 0.01∗
30min‡ 678.3 ± 155.5 0.41 640.7 ± 119.9 0.34 662.2 ± 167.9 0.75
60min† 618.3 ± 177.0 0.71 598.9 ± 135.0 0.39 611.7 ± 115.6 0.89
60min‡ 698.4 ± 148.0 0.12 629.9 ± 94.9 0.83 619.8 ± 166.6 0.11
All values given in nmol/L to convert to mg/dL are divided by 27.59.
∗Significant at 𝑃 ≤ 0.05, paired 𝑡-test.
†Cases documented with primary hypothyroidism at baseline.
‡Values obtained in cases after LT-4 tratment.
Table 4: Comparative cortisol values to cosyntropin after LT-4
replacement therapy between cases and their age-matched controls
(nmol/L).
Cases (𝑛 = 60) Controls (𝑛 = 60) 𝑃 value
All (𝑛 = 60)
0min 367.5 ± 149.1 369.2 ± 91.4 0.93
30min 653.2 ± 138.3 677.0 ± 82.4 0.25
60min 661.6 ± 144.4 669.9 ± 83.7 0.89
Group 1 (𝑛 = 30)
0min 391.9 ± 176.3 383.3 ± 110.5 0.82
30min 678.3 ± 155.5 673.2.0 ± 79.1 0.87
60min 698.4 ± 148.0 679.1 ± 95.6 0.54
Group 2 (𝑛 = 15)
0min 302.3 ± 87.4 348.6 ± 85.9 0.15
30min 640.7 ± 119.9 663.7 ± 108.1 0.43
60min 629.9 ± 94.9 686.5 ± 66.3 0.07
Group 3 (𝑛 = 15)
0min 442.5 ± 198.4 361.7 ± 40.4 0.13
30min 662.1 ± 167.8 687.9 ± 61.6 0.58
60min 619.7 ± 166.3 634.8 ± 66.32 0.74
All values given in nmol/L to convert to mg/dL are divided by 27.59.
3.4. Longitudinal Comparisons of Cortisol Values (before ver-
sus after Levothyroxine Replacement)
3.4.1. Longitudinal Comparison of Cortisol Values in the Case
Group. When cases were compared before and after L-
T4 therapy, mean serum cortisol values were lower before
thyroid hormone normalization. Nevertheless, statistical sig-
nificance was found only at 30-minute time (612.6 ± 133.1
versus 653.2 ± 138.3 nmol/L). 𝑃 = 0.04. See Table 4.
3.4.2. Longitudinal Comparison of Cortisol Values by Groups
(Subclinical, Mild/Moderate, and Severe). The mean cortisol
values at baseline and after stimulation with cosyntropin
when compared before and after levothyroxine in group 1
showed lower values before L-T4 replacement but statistical
significance was reached only at 60-minute time (𝑃 = 0.03).
In group 2 there was no statistically significant difference
between mean cortisol values before and after L-T4 therapy.
Table 5: Comparative cortisol values to cosyntropin after LT-4





(𝑛 = 60) 𝑃
All (𝑛 = 60)
0min 357.3 ± 144.8 367.5 ± 149.1 0.70
30min 612.6 ± 133.1 653.2 ± 138.3 0.04∗
60min 603.4 ± 153.7 661.6 ± 144.4 0.06
Group 1 (𝑛 = 30)
0min 384.6 ± 152.2 391.9 ± 176.3 0.86
30min 652.5 ± 101.3 678.3 ± 155.5 0.44
60min 618.3 ± 177.0 698.4 ± 148.0 0.03∗
Group 2 (𝑛 = 15)
0min 346.9 ± 148.5 302.3 ± 87.4 0.32
30min 636.5 ± 112.8 640.7 ± 119.9 0.92
60min 598.9 ± 135.0 629.9 ± 94.9 0.47
Group 3 (𝑛 = 15)
0min 348.9 ± 157.5 442.5 ± 198.4 0.02∗
30min 540.9 ± 178.7 662.1 ± 167.8 0.01∗
60min 611.7 ± 115.6 619.7 ± 166.3 0.84
All values given in nmol/L to convert to mg/dL are divided by 27.59.
∗Significant at 𝑃 of ≤0.05.
In group 3 themean cortisol values at baseline and 30-minute
time were statistically lower before L-T4 (𝑃 = 0.02 and 0.01,
resp.). See Table 5.
3.5. Glucocorticoid Functional Insufficiency before and after
L-T4 Therapy. Taking 500 nmol/L or more as the normal
cortisol response at 30 or 60 minutes after cosyntropin
stimulation, 4 out of 60 cases (6.7%) had insufficient gluco-
corticoid reserve before L-T4 treatment, one of them in group
1 and three in group 3. After L-T4 therapy 2 out of 4 cases
reached a normal cortisol response and the other two cases
(both in group 3) stayed with glucocorticoid insufficiency.
They had an elevated plasma adrenocorticotropic level (291
and 443 pg/mL; normal range: less than 46 pg/mL) and
glucocorticoid replacement therapy was initiated. Adrenal
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cortex antibodies were not carried out. When a cortisol value
of 550 nmol/L or more was taken as the normal cortisol
response, 11 out of 60 cases (18.3%) had an abnormal cortisol
response to cosyntropin at 30 and 60min, six of them in
group 3, three in group 2, and two in group 1. After L-T4
replacement 9 out of 11 cases (81.8%) showed anormal cortisol
response.The two persistent abnormal cases were in group 3.
In the control group, all of the participants had an adequate
cortisol response after cosyntropin stimulation at 30 or 60
minutes with both 500 nmol/L and 550 nmol/L cutoff values.
4. Discussion
In this prospective study of patients with different degrees
of intensity of primary hypothyroidism we found with the
low-dose cosyntropin test that their serum cortisol response
before L-T4 replacement therapy was significantly lower
than controls. After thyroid hormone level normalization, an
increase in their cortisol response was observed and this dif-
ference was lost.This change was primarily due to an increase
in the cortisol response in the severe hypothyroidism group.
The analysis by group of cases (subclinical, mild/moderated,
and severe) after L-T4 therapy showed a modest but signif-
icant increase in cortisol response at 0 and 30 minutes in
the severe hypothyroidism group and at 60 minutes in the
subclinical hypothyroidism group. Remarkably, 4 out of 60
cases (6.7%) with 500 nmol/L as the cortisol cutoff value and
11 out of 60 cases (18.3%) with the 550 nmol/L as a cutoff had
an abnormal cortisol response (adrenal insufficiency) that
reverted after L-T4 therapy in 2 (50%) and 9 cases (81.8%),
respectively, without any other treatment.
It has been generally accepted that adrenal functionmight
be impaired in patients with primary hypothyroidism. In
1957, Peterson in seven patients with severe hypothyroidism
described that cortisol secretion and synthesis were reduced,
primarily due to an impairment of cortisol metabolism by
the liver. After L-T4 therapy was initiated cortisol pro-
duction returned to normal. However, not every patient
was evaluated after L-T4 therapy and adrenal function was
not assessed using a stimulation test [8]. Later, in patients
with primary hypothyroidism, Macgregor and Lessof et al.
proposed an insufficient adrenal response to ACTH stim-
ulation and an impairment of pituitary function, respec-
tively [9, 10]. On the other hand, a normal HPA axis
in patients with primary hypothyroidism has also been
reported [11, 14]. In 1970, in a study by Harvard et al., in
seven patients with primary hypothyroidism and in three
with secondary hypothyroidism, adrenal stimulation with
a standard ACTH test showed a normal cortisol response
at 30 and 60min in all patients before L-T4 therapy. This
remained unchanged after achieving euthyroidism. Never-
theless, in that same study insulin-induced hypoglycemia
produced a significant increase in cortisol response after
L-T4 treatment [11]. Recently, U¨nlu¨hizarci et al. evaluated
the HPA axis comparing the low-dose versus standard dose
cosyntropin test before L-T4 therapy in 14 patients with
severe primary hypothyroidism (TSH > 100 𝜇U/mL) [14].
The cortisol response in cases, although higher with the
standard cosyntropin dose, was not statistically different.
Interestingly, in these patients, cortisol response with either
test was not statistically different from the cortisol response
of the control group, suggesting that adrenal function was
not impaired in primary hypothyroidism. Assessment of the
cortisol response after L-T4 therapy was not carried out
[14]. In the present study, we describe the cortisol response
using the low-dose cosyntropin test in full-spectrum primary
hypothyroidism patients (subclinical, mild/moderate, and
severe) before and after normalization of thyroid function
tests. When these patients were compared with age- and
gender-matched controls an improved cortisol response was
found, and so was reversal of adrenocortical insufficiency in
over 50% of the cases after L-T4 therapy.
The exact site and how the HPA axis is impaired by
hypothyroidism are still not well elucidated. It has been
described that thyroidectomy decreases plasma ACTH levels
(even though the pituitary content of ACTH might be
increased) due to a reduction in corticotropin releasing
hormone (CRH) gene expression in the hypothalamus [22,
23]. Additionally, in hypothyroid-induced rats, a reduction in
ACTHand a significant decrease in adrenal weight alongwith
an increase of ACTH to CRH stimulation suggest a central
adrenal insufficiency mediated by low thyroid hormone
levels that has been described to be more pronounced as
the duration and intensity of thyroid dysfunction increase.
This situation has been explained by decreased CRH mRNA
expression in the hypothalamic paraventricular nucleus.
At the adrenal level, in long-standing hypothyroidism, a
significant reduction in cortisol secretion after ACTH has
been documented in primary adrenal cell culture [15]. This
finding was also supported by Tohei et al. who suggest that
hypothyroidism directly causes adrenal dysfunction and that
hypersecretion of CRH and arginine vasopressin is due to
a reduction in the negative feedback effect of glucocorti-
coids [23]. In our study, ACTH levels were mildly elevated
in hypothyroid patients that had an inadequate cortisol
response to cosyntropin before L-T4 therapy. Remarkably,
adrenal function was completely restored after reaching a
euthyroid state in 9 out of 11 patients using the 550 nmol/L
cortisol cutoff value. These results suggest a direct (adrenal
level) and transitory rather than permanent adrenal dys-
function provoked by low concentration of thyroid hormone
levels. As previously reported in rats, most of our cases were
from the severe hypothyroidism group. However, between
25–50% of patients in the mild/moderate groups also had an
initial abnormal cortisol response that was normalized in all
cases after successful L-T4 therapy.
Interestingly, cortisol response to cosyntropin was not
impaired in all hypothyroid patients. This suggests that even
though low serum thyroid hormones play an important role
in adrenal dysfunction, there are other associated factors
that still have to be recognized. Two of our cases remained
with adrenal insufficiency despite adequate L-T4 therapy.
Both were from the severe hypothyroidism group and even
though the possibility of a permanent adrenal dysfunction
due to low thyroid hormone levels is plausible, it is important
to remember the link between hypothyroidism and adrenal
insufficiency. It is likely that these cases could have an
underlying autoimmune etiology.
6 International Journal of Endocrinology
It is worthy to mention that even though cortisol levels
improved after L-T4 therapy mean basal and stimulated cor-
tisol levels in the case group were within normal range in all
subgroups. When this data is seen as a whole, it suggests that
in primary hypothyroidism there is an impaired HPA axis
that improves with L-T4 therapy. Nonetheless, this condition
will probably have a discrete, if at all, clinical significance as
cortisol levels at baseline and after cosyntropin stimulation
before and after L-T4 therapy remained within normal range.
However, when each case is viewed separately, 4 out of 60
cases (6.7%) with a cortisol cutoff value of 500mmol/L and
11 out of 60 (18.3%) with a cutoff of 550mmol/L had adrenal
insufficiency before L-T4 therapy. Remarkably, 50% and 81%
of the cases had a normal cortisol response after L-T4 therapy
without any other treatment. Most of the cases (>50%) were
in the severe hypothyroidism group, suggesting, as previously
described in rats, that a prolonged state of hypothyroidism
might deeply impair cortisol secretion [16]. Nevertheless, in
our study, 25–50%of the cases of adrenal insufficiencywere in
the subclinical-mild/moderate hypothyroidism groups. This
feature has important clinical implications since we confirm
the necessity of assessing adrenal function with the low
cosyntropin test in all severe hypothyroidism cases. Due to
the high incidence of compensated/mild hypothyroidism we
have a strong clinical suspicion of the coexistence of transient
adrenocortical insufficiency. In these cases, a low-doseACTH
test could be performed. A clinical scenario could be in
situations of acute stress which occur while a euthyroid state
is still not achieved and that, if not treated, could otherwise
potentially lead to an acute adrenal crisis. A cortisol value
at 30 or 60 minutes after cosyntropin stimulation greater
than 550 nmol/L in all subjects in the control group strongly
supports the important role of thyroid hormones in HPA
axis dysfunction and suggests that 550 nmol/L might be a
better serum cortisol cutoff for the diagnosis of an insufficient
adrenocortical response.
A direct TSH elevation secondary to adrenal insufficiency
with reversal of thyroid function after glucocorticoid replace-
ment has been described [12, 24–26]. In 1980, Topliss et al.
reported that six out of ten patients with primary adrenal
insufficiency had a mild/moderate increase in TSH levels
that reversed to normal values after glucocorticoid therapy.
Interestingly, TSH oscillations occurred without a change in
thyroid hormone levels. In all patients rT
3
levels were the
same before and after treatment suggesting that TSH could
be increased as a direct effect of adrenal deficiency without
thyroid dysfunction. Thyroid antibodies in all six patients
were negative. The patients in whom TSH remained high
had positive thyroid antibodies and higher TSH levels. The
proposed mechanism was that low cortisol levels cause a
rise in pro-TRH mRNA in the hypothalamic paraventricular
nucleus with a consequent increase of TSH levels [12].
Barnett et al. reported similar findings in five patients with
Addison’s disease andTSH elevation. In all of these cases anti-
thyroglobulin or thyroid peroxidase antibodies were positive
and only one case remained euthyroid without thyroid
replacement after glucocorticoid therapy. Remarkably, six out
of eleven patients with Addison’s disease had normal thyroid
function tests [25]. In our study, all cases had documented
low TT4 and FT4 with positive thyroid antibodies. Only
two of the eleven cases with inadequate adrenal response
did not recover after L-T4 therapy, both cases were from the
severe hypothyroidism group. In all cases of mild/moderate
hypothyroidism, cortisol response to cosyntropin became
normal after L-T4 therapy. This suggests that even though
TSH levels could have increased because of glucocorticoid
deficiency, these were only exacerbated by this phenomenon
rather than being the primary cause.
It has been debated for a long timewhich test (low or stan-
dard dose) cortisol stimulation has better performance. Based
on the concept that 250 𝜇g of cosyntropin is a pharmacologic
rather that a physiologic stimulus that may stimulate partial
atrophied or mildly dysfunctional adrenal glands, multiple
studies have demonstrated that the low-dose cosyntropin test
has better or equal results than the standard test. Particularly,
in the setting of chronic partial pituitary ACTH deficiency
and recent onset ACTH deficiency, low-dose stimulation
has demonstrated a better performance [18, 19, 27–33]. This
is a strength of our study since most of the patients with
abnormal response to low-dose cosyntropin (1𝜇g) had a near-
normal/partial abnormal cortisol response that could have
been otherwise overestimated if we had used the standard
250 𝜇g cosyntropin test.
In conclusion, this prospective study of patients with
different severities of primary hypothyroidism showed, using
the low-dose cosyntropin test, an improved cortisol response
after normalization of thyroid hormone levels. The mecha-
nism of impaired cortisol secretion in cases with hypothy-
roidism still has to be elucidated but our data support an
adrenal rather than a pituitary affection. The incidence of
adrenal insufficiency was 6.7–18.3% and more than 50%
of the cases had a normal cortisol response after L-T4
therapy. Remarkably, 25–50% of the cases were in the sub-
clinical/mild/moderate hypothyroidism groups. This finding
could have important clinical implications especially in the
setting of acute stress situations occurring during the period
while a euthyroid state is still not achieved.
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